BiolineRx

About BiolineRx

BioLineRx Ltd. is a publicly traded biopharmaceutical company established in 2003 as a joint venture involving Teva, Hadasit Bio-Holdings, and the Jerusalem Development Authority, among others. The company focuses on oncology and rare diseases, operating from its headquarters in Modi'in, Israel. Philip A. Serlin has served as Chief Executive Officer since October 2016, having previously joined the company in 2009 as its Chief Financial and Operating Officer. His background includes a B.Sc. in Accounting from Yeshiva University, a Master's in Economics and Public Policy from George Washington University, and prior roles at the U.S. Securities and Exchange Commission and Deloitte. He leads a management team that includes Chief Development Officer Ella Sorani, who brought extensive experience from Teva Pharmaceutical Industries when she joined.

The company’s business model is centered on in-licensing promising drug candidates, primarily from Israeli academic institutions and biotech firms, and advancing them through clinical trials before seeking partnerships for late-stage development and commercialization. A significant milestone was achieved in September 2023 when the U.S. Food and Drug Administration (FDA) approved its first product, APHEXDA® (motixafortide). Following this approval, BioLineRx shifted its strategy to a more royalty-driven model, out-licensing the commercialization rights for APHEXDA® to reduce operational costs and secure revenue through milestones and royalties. This includes agreements with Ayrmid Ltd. for markets outside of Asia and with Gloria Biosciences for development and commercialization in Asia.

APHEXDA® (motixafortide) is a hematopoietic stem cell mobilizer administered via subcutaneous injection. It is indicated for use in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in adult patients with multiple myeloma. As a selective antagonist of the CXCR4 receptor, motixafortide blocks the mechanism that anchors stem cells in the bone marrow, thereby increasing their numbers in the peripheral blood for collection. This was the first new stem cell mobilization therapy approved for multiple myeloma in a decade. Beyond its approved use, motixafortide is under investigation for other applications, including mobilizing stem cells for gene therapies in sickle cell disease and as a combination therapy for pancreatic cancer. The company actively collaborates with academic institutions like Columbia University and Washington University School of Medicine, and industry partners such as Merck and Regeneron, to explore the full potential of its pipeline.